For medical device companies that have navigated the FDA regulatory pathway, the prospect of a separate EU MDR submission can feel daunting. But the good news is that much of the hard work you’ve already done doesn’t have to be repeated from scratch. A significant portion of your FDA submission can be repurposed, adapted and leveraged to accelerate your route to CE marking if you know where to look. 

Here are four key areas where your existing data can work harder for you. 

Clinical Investigations 

If your clinical studies were conducted in line with ISO 14155 Good Clinical Practice (GCP) standards, they are well-positioned to translate directly into your EU MDR clinical evaluation. The EU MDR places considerable emphasis on robust clinical evidence, and studies that meet ISO 14155, regardless of where they were conducted, can form a cornerstone of your Clinical Evaluation Report (CER). The key is ensuring your study design, endpoints and patient population align with your intended EU indication. 

Independently Published Studies 

Published literature is a powerful and often underutilised asset. Peer-reviewed studies demonstrating your device’s safety and performance in its intended patient population and for its intended use can be incorporated into your clinical evidence base. Under EU MDR, a thorough literature search and critical appraisal is not optional. It’s a regulatory requirement. If strong independent evidence already exists for your device or equivalent devices, this can substantially reduce the burden of generating new clinical data. 

Real World Evidence 

Post-market experience is increasingly valued under EU MDR, and data collected from real-world use of your device in the US market is directly relevant. This includes device registries, user surveys, complaint data and any other structured collection of experience across all settings and patient populations normally exposed to the device. Well-documented real-world evidence not only supports your clinical evaluation but also forms the foundation of your Post-Market Clinical Follow-up (PMCF) plan, which is a requirement that catches many manufacturers off guard. 

FDA Post-Market Surveillance Data 

Data collected as part of your ongoing US post-market surveillance activities can be repurposed for EU MDR purposes. MDR/MDV reports, complaint trends, field safety data and periodic safety update reports all provide valuable insights into your device’s performance in the real world. With some repositioning, this data can feed directly into your EU Technical Documentation and support a robust benefit-risk profile. 

Overall 

EU MDR is demanding, but it doesn’t require you to start from zero. The regulatory pathways are different, but the underlying questions are the same: is this device safe, does it perform as intended and is the benefit-risk profile acceptable? If your FDA submission answers those questions well, you’re already further along the EU MDR journey than you might think. 

The key is knowing how to bridge the two frameworks and that’s where experienced medtech clinical and regulatory expertise makes all the difference. 

If any part of your clinical trial journey feels uncertain, whether that’s full-service CRO support or just getting your EU MDR submission over the line, feel free to book a call and we can figure out the best way to help. Click here